Creo Medical Group PLC (AIM:CREO), a medical device firm specialising in minimally invasive surgical endoscopy, said that the Royal Oldham Hospital has swiftly adopted its CROMA and Speedboat Inject technologies.
In May, the Royal Oldham became the first NHS institution to adopt these tools across multiple endoscopy rooms, scheduling regular Speedboat submucosal dissection(SSD) cases.
The hospital has since treated over 40 patients through this service, marking the quickest such adoption by any NHS facility.
This has yielded notable outcomes for patients, the institution, and its personnel. Several doctors at Royal Oldham have completed Creo's Pioneer Programme mentoring phase and now independently handle routine cases involving intricate, high-risk colon lesions.
Creo's Speedboat product line aims to cater to over 350 NHS hospitals. Each SSD operation can potentially save the NHS up to £10,000 compared to conventional surgery.
This is coupled with typically shorter hospitalisations and reduced complication risk. To date, 23 NHS England healthcare centres have incorporated SSD.
"Oldham provides a phenomenal model for what's possible when a hospital immediately recognises the potential of the device and implements the right pathways and resource to maximise its impact," said chief executive Craig Gulliford.
"To know that there are 40 patients in and around Oldham who have already benefited from our technology and the excellent service provided by Dr Khalid and his team is incredibly gratifying, with the knock-on positive effects on waiting lists and hospital resources now well established."